Skip to main content


Figure 4 | Journal of Translational Medicine

Figure 4

From: Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer

Figure 4

Injury and repair surrogates trend with outcome in PBMCs from women treated with O/C. PBMCs obtained from 15 women pretreated with O/C and viably frozen were available and analyzed according to our demonstrated SOP. The graphed values in y axis are raw MFI levels as they represent data from patient samples taken at only one time point (before O/C treatment). a γH2AX; b MRE11. Median MFI levels of γH2AX (c) and MRE11 (d) were lower in patients with objective measurable responses to O/C. A pretreatment ratio of γH2AX/MRE11 was significantly higher in patients with no measurable response to O/C (e). Pre-treatment γH2AX (f), MRE11 (g) and a ratio of γH2AX/MRE11 (h) by dual-label flow cytometry are lower in gBRCAm patients compared with BRCAwt patients.

Back to article page